866-997-4948(US-Canada Toll Free)

Other Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 125 Pages


Global Markets Directs, \'Other Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Other Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Cancer. 

Other Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Other Cancer.
  • A review of the Other Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Other Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Other Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Other Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Other Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Other Cancer 9
Other Cancer Therapeutics under Development by Companies 11
Other Cancer Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Other Cancer Therapeutics Products under Development by Companies 20
Other Cancer Therapeutics Products under Investigation by Universities/Institutes 21
Companies Involved in Other Cancer Therapeutics Development 24
Selecta Biosciences, Inc. 24
Other Cancer Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 32
3F8-Mab - Drug Profile 32
tirapazamine - Drug Profile 33
Gemcitabine + Oxaliplatin + Erlotinib - Drug Profile 34
GM-CSF + Dendritic Cell-Tumor Fusion Vaccine + Imiquimod - Drug Profile 36
Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile 38
Aldesleukin + Radiation Therapy - Drug Profile 39
Esomeprazole + Aspirin - Drug Profile 41
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile 43
Gemcitabine Hydrochloride + Cisplatin - Drug Profile 45
Cisplatin + Triapine - Drug Profile 46
Acyclovir + Acyclovir sodium + Valacyclovir - Drug Profile 47
WT1-Specific T Cells + Filgrastim + Cyclophosphamide + Fludarabine - Drug Profile 49
Capecitabine + Oxaliplatin - Drug Profile 51
Fludarabine phosphate + Busulfan + Alemtuzumab + Tacrolimus + Allogeneic hematopoietic stem cell transplantation - Drug Profile 52
NTX-010 - Drug Profile 54
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 55
HeFi-1 - Drug Profile 57
Oxaliplatin + Capecitabine +Radiation Therapy - Drug Profile 58
Fosaprepitant dimeglumine + Dexamethasone + Palonosetron - Drug Profile 60
Bevacizumab + Oxaliplatin + Paclitaxel - Drug Profile 62
Valproic acid + Bevacizumab + Radiation therapy - Drug Profile 63
Cisplatin + Fluorouracil - Drug Profile 65
Cisplatin + Fluorouracil - Drug Profile 67
Cisplatin + Fluorouracil + Brachytherapy + Radiation Therapy - Drug Profile 69
FOLFIRI + Cisplatin - Drug Profile 71
FOLFOX + Cetuximab - Drug Profile 73
Alvocidib + Depsipeptide - Drug Profile 75
imatinib mesylate - Drug Profile 76
Carboplatin + Taxotere + Gemcitabine - Drug Profile 77
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 79
Filgrastim + Cisplatin + Ppaclitaxel + Radiation Therapy - Drug Profile 81
Filgrastim + Cisplatin + Ppaclitaxel + Radiation Therapy - Drug Profile 83
Cisplatin + Etoposide + Adriamycin + Cyclophosphamide - Drug Profile 85
imatinib - Drug Profile 87
Irinotecan + Gemcitabine - Drug Profile 88
Recombinant Interleukin-12 + Trastuzumab - Drug Profile 89
Imatinib Mesylate + Interferon + Vincristine + Dexamethasone - Drug Profile 90
alemtuzumab + cyclophosphamide + methotrexate + tacrolimus - Drug Profile 92
Cisplatin + Irinotecan - Drug Profile 94
Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile 96
Filgrastim + Cytarabine - Drug Profile 98
Procarbazine hydrochloride + thalidomide - Drug Profile 99
Taxol + Hycamtin - Drug Profile 100
Allogeneic Tumor Cell Vaccine + Iscomatrix + Celecoxib + Cyclophosphamide - Drug Profile 101
Cisplatin + Etoposide + Radiotherapy_ - Drug Profile 103
Cisplatin + Ifosfamide + Paclitaxel - Drug Profile 104
methylphenidate hydrochloride - Drug Profile 105
methylphenidate hydrochloride - Drug Profile 106
temsirolimus - Drug Profile 107
CIGB-552 - Drug Profile 108
tSVP For Other Cancer - Drug Profile 109
Other Cancer Therapeutics Drug Profile Updates 110
Other Cancer Therapeutics Discontinued Products 111
Other Cancer Therapeutics - Dormant Products 112
Other Cancer Product Development Milestones 114
Featured News & Press Releases 114

Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 122
Disclaimer 122

List of Table


Number of Products Under Development for Other Cancer, H2 2012 12
Products under Development for Other Cancer Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Selecta Biosciences, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 34
Other Cancer Therapeutics Drug Profile Updates 113
Other Cancer Therapeutics Discontinued Products 114
Other Cancer Therapeutics Dormant Products 115
Other Cancer Therapeutics Dormant Products (Contd..1) 116

List of Chart


Number of Products under Development for Other Cancer, H2 2012 12
Products under Development for Other Cancer Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *